Karuna Therapeutics Inc (KRTX)

$169.09 1.16 (0.68%)

16:00 EDT KRTX Stock Quote Delayed 30 Minutes

Why Is Karuna Therapeutics (KRTX) Stock Moving Today?

By William White, InvestorPlace Writer Mar 20, 2023

Karuna Therapeutics (KRTX) stock is on the move Monday after releasing positive results from a Phase 3 clinical trial for KarXT.

7 Momentum Stocks to Buy Now for Extraordinary Gains

Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data

7 Risky Stocks to Buy Now for Growth and Exciting Returns

More Articles

Volume:

Previous Close -

Market Cap 6.33B

PE Ratio -22.85

EPS -7.4

Volume (Avg. Vol.) 295,366

Day's Range $166.27 - $172.35

52-Week Range $159.73 - $240.59

Dividend & Yield N/A (N/A)

KRTX Stock Predictions, Articles, and Karuna Therapeutics Inc News

From InvestorPlace
From the Web

The Top Performing Sector in 2020 Will Be …

By InvestorPlace Research Staff Feb 19, 2020

The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.

The Price of Karuna Therapeutics Stock Is Too Tough to Swallow

By Josh Enomoto, InvestorPlace Contributor Dec 17, 2019

In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.

What to Do with Karuna Stock After It Soared and Then Plunged

By Chris Lau, InvestorPlace Contributor Dec 13, 2019

Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock. So, after the cash raise torpedoed the....

Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trial

By William White, InvestorPlace Writer Nov 18, 2019

Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring.

Wells Fargo starts Karuna at overweight, cites schizophrenia drug candidate (KRTX)

From Seeking Alpha Aug 22, 2023

Wells Fargo has initiated coverage of Karuna Therapeutics (KRTX) with an overweight rating, positing the company’s schizophrenia drug candidate KarXT could become a $3.2B product.

Karuna Therapeutics GAAP EPS of -$2.75 beats by $0.09 (NASDAQ:KRTX)

From Seeking Alpha Aug 3, 2023

Karuna Therapeutics press release (KRTX): Q2 GAAP EPS of -$2.75 beats by $0.09.Announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion...

3 Biotech Buyout Targets to Watch

From The Motley Fool Apr 29, 2023

The trio all have late-stage therapies with blockbuster potential.

Why Shares of Karuna Therapeutics Were Up Wednesday

From The Motley Fool Mar 22, 2023

The clinical-stage biotech announced positive trial results for its lead therapy.

Karuna Therapeutics prices ~$400M stock offering (NASDAQ:KRTX)

From Seeking Alpha Mar 22, 2023

Karuna Therapeutics (KRTX) on Tuesday has priced an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33/share, for expected...

Mizuho Securities Reaffirms Their Buy Rating on Karuna Therapeutics (KRTX)

From TipRanks Dec 8, 2022

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Karuna Therapeutics (KRTX – Research Report) today and set a price target of...